Mickey D D, Carvalho L, Foulkes K
Department of Surgery, University of North Carolina, Chapel Hill.
J Urol. 1989 Dec;142(6):1594-8. doi: 10.1016/s0022-5347(17)39175-9.
Growth alteration effects of an immunomodulator, PSK, were investigated individually and in association with conventional chemotherapeutic agents cyclophosphamide, cisplatin and fluorouracil in an experimental prostatic cancer model. Copenhagen rats had subcutaneous tumors induced by injections of cells cultured in vitro from a highly metastatic hormonally unresponsive subline of the Dunning rat prostatic tumor, MAT-LyLu. Treatment with conventional agents and the immunomodulator agent individually and in combination began three days after tumor cell inoculation. PSK used alone was not able to significantly influence tumor growth. In appropriate doses, each conventional agent significantly retarded tumor growth. Used in combination, PSK and conventional agents retarded tumor growth locally and decreased metastatic spread of the tumor. Animals receiving combination therapy had increased life spans over those animals receiving single standard chemotherapeutic agents. Immunomodulation with PSK may enhance the antineoplastic effects of chemotherapeutic agents and offer a treatment option for hormone resistant prostatic cancer.
在一个实验性前列腺癌模型中，研究了免疫调节剂PSK单独以及与传统化疗药物环磷酰胺、顺铂和氟尿嘧啶联合使用时对生长的改变作用。哥本哈根大鼠通过注射来自邓宁大鼠前列腺肿瘤高转移性激素无反应亚系MAT-LyLu体外培养的细胞诱导皮下肿瘤。在肿瘤细胞接种三天后开始单独及联合使用传统药物和免疫调节剂进行治疗。单独使用PSK不能显著影响肿瘤生长。在适当剂量下，每种传统药物都能显著延缓肿瘤生长。PSK与传统药物联合使用可局部延缓肿瘤生长并减少肿瘤的转移扩散。接受联合治疗的动物比接受单一标准化疗药物的动物寿命更长。用PSK进行免疫调节可能会增强化疗药物的抗肿瘤作用，并为激素抵抗性前列腺癌提供一种治疗选择。
